• Age ≥ 18 years;

• Signed ICF, including consent for FFPE tumor tissue sample testing;

• Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry;

• For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature:

‣ T1 tumor

⁃ High grade/G3 tumor

⁃ CIS (carcinoma in situ)

⁃ Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point);

• For patients with MIBC: Сystectomy performed at least 2 months but not more than 12 months prior to study entry;

• For patients with mBC: mBC diagnosed during 12 months prior to study entry;

• Availability of medical history data;

• Availability of FFPE tumour tissue sample obtained during biopsy and/or surgery.